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The number of lives saved by antibiotics is a hallmark of the success of this class of drugs. However, resistant bacterial strains have been identified for every class of antibiotic, usually within a few years of general therapeutic use. [1] [2] [3] The threat of antibiotic resistance is epitomized by the emergence of six multi-drug resistant bacteria referred to as the ESKAPE pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. [4] [5] [6] [7] [8] The Center for Disease Control (CDC) Antibiotic Resistance Threat Report lists these bacteria as serious threats (level 4 out of 5) requiring prompt and sustained action. 9 Most alarming is that antibiotic resistance has mounted to the point where therapeutics are severely limited or ineffective for once easily treated infections. For example, ~10,000 people per year are estimated to die from methicillin-resistant S. aureus (MRSA) infections in the United States. 10 Moreover, the CDC estimates the direct medical cost of treating antibiotic resistant bacterial infections in the US is more than $20 billion per year. 9 Clearly, the rise of resistant bacterial strains requires enhanced research efforts to ensure an ongoing antibiotic pipeline.
Current antibiotics primarily function by blocking cell wall construction, structure and function of the cell membrane, protein synthesis, DNA structure and function, or folic acid synthesis. 11 Recently developed therapeutics for infections caused by drug-resistant bacteria include the injectable carbapenem beta-lactam, doripenem, which targets penicillin-binding proteins and inhibits cell wall synthesis; 12 the cyclic lipopeptide, daptomycin, which inserts into the bacterial membrane and leads to pore formation; 13 quinupristin/dalfopristin, which bind to two different sites on the 50S ribosomal subunit and interfere with protein synthesis; 14 the oxazolidinone, linezolid, which also binds the 50S ribosomal subunit; 15 the tetracycline derivative, tigecycline, which targets protein synthesis via the 30S ribosomal subunit; 16 and the 4 lipoglycopeptide, dalbavancin, which has the same mode of action as vancomycin, binding to the D-Ala-D-Ala motif in the cell wall. 17 As these examples illustrate, most new antibiotics are derivatives of existing drugs that also target the aforementioned pathways. Unfortunately, bacterial resistance to these drugs is quick to develop. These data argue for the continued pursuit of antibiotics with entirely new modes of action, which may better avoid mechanisms of resistance and have longer effective life times. General protocol for chaperonin-mediated biochemical assays. Compounds (I) are added at point A to a solution containing GroEL (or HSP60) with bound substrate protein (e.g. malate dehydrogenase, MDH). Addition of GroES (or HSP10) and ATP initiates the refolding cycle, which is quenched with EDTA after a 60 minute incubation. Substrates (R) for the refolded reporter enzyme are added and after another 30-60 minute incubation (until the DMSO control wells have reached ~90% consumption of NADH), absorbance is measured to evaluate the amount of refolded enzyme present, and by association the extent of chaperonin inhibition. Alternatively, addition of compounds at point B enables determination of off-target inhibition of the reporter enzyme (i.e. native MDH enzyme activity). Chaperonin-mediated ATP hydrolysis is also evaluated using a malachite green assay. Biochemical assays employing Rhodanese (Rho) are performed similarly (refer to the Supporting Information for detailed protocols).
An attractive strategy for the development of novel antibiotics is to target bacterial protein homeostasis (proteostasis) mechanisms, in particular molecular chaperones. Molecular chaperones are a specialized class of proteins that help other proteins to properly fold to their native states. Among the molecular chaperones in E. coli, the GroEL/ES chaperonin system is the only one essential for growth under all conditions. 18, 19 GroEL is a central processing 5 machine that maintains the structural and functional integrity of many other proteins ( Figure 1) ; for a review, see references 19 and 20. [19] [20] [21] [22] Thus, targeting this one functional node results in a cascading effect that leads to the dysfunction of numerous key cellular pathways, which is lethal to bacteria. 18 Because no other drugs function by targeting chaperonin systems, this strategy should be effective against bacteria that are resistant to current antibiotics.
The central tenet of this antibiotic strategy raises the question of whether bacterial GroEL/ES can be targeted specifically without interfering with the metazoan counterpart in the mitochondria, HSP60/10, whose partial deficiency in humans leads to disease. 23 Human HSP60
shares 48% sequence identity with E. coli GroEL, and thus there is the possibility of inhibitor cross-talk between the two chaperonins. However, structural and functional differences between the two systems suggest that it should be possible to develop inhibitors that selectively target bacterial GroEL/ES over human HSP60/10. GroEL is a homo-tetradecameric protein consisting of two, seven-membered rings that stack back-to-back. [24] [25] [26] Through a series of events driven by ATP binding and hydrolysis, unfolded substrate proteins are bound within the central cavity of one GroEL ring and encapsulated by the heptameric GroES co-chaperonin lid structure, triggering protein folding in a sequestered chamber. [25] [26] [27] [28] [29] [30] [31] GroEL/ES works as an allostericallycontrolled, double-ring system, which is regulated through positive intra-ring ATP-binding and negative inter-ring binding. In contrast, studies have indicated that human HSP60/10 operates as a single-ring species, through at least part of the cycle, removing many of the intermediate states associated with the GroEL/ES refolding cycle.
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Thus, it should be possible to develop inhibitors that selectively target the double-ring GroEL/ES cycle with its additional allosteric signals and conformational intermediates. Furthermore, HSP60/10 is in the mitochondrial matrix, which is often protected from small molecule penetration; thus, even if compounds are 6 found that inhibit HSP60/10 in biochemical assays, they may not display cytotoxicity if they failed to reach the mitochondrial matrix.
We previously developed a series of compounds that bind to the ATP sites of E. coli GroEL and inhibit the chaperonin refolding cycle. 35, 36 We also conducted a high-throughput screen to discover inhibitors of the E. coli GroEL/ES chaperonin system that target sites other than the ATP pockets, as we had concerns that ATP-competitive inhibitors may have off-target effects against other ATP-dependent proteins in cells. 37 We chose the E. coli GroEL/ES homolog for screening because it is the best characterized chaperonin and has been a model system for studying this class of proteins. 30, 31, [38] [39] [40] It shares high homology with GroEL/ES systems from other bacteria, with 56-97% identical amino acids for GroEL and 44-94% identical amino acids for GroES (refer to Table S1 in the Supporting Information). Thus, E. coli GroEL/ES serves as an excellent surrogate to discover chaperonin inhibitors to treat bacterial infections. The assays we developed analyzed the full refolding cycle and used the substrate reporter enzymes -arylsulfotransferase IV (AST-IV) and malate dehydrogenase (MDH), which require GroEL, GroES, and ATP in order to return to their native, active states (refer to Figure 1 for a general overview of the assay protocols). From ~700,000 molecules, our high-throughput screening narrowed the number of GroEL/ES inhibitors to 235. We investigated a subset of these hits in greater detail to identify IC50 values for inhibiting GroEL/ES-mediated substrate refolding and ATPase activity. While only a few compounds inhibited GroEL/ES-mediated ATPase activity, most were potent inhibitors of the refolding cycle and exhibited minimal to no off-target effects against the reporter enzyme.
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Figure 2. Structures of the 22 compounds under evaluation. For ease of comparison, compound numbering from 1-36 was maintained as presented in our previous high-throughput screening study.
Compounds 2-4, 6, 7, 12, 13, 16, 17, 21, 22, 26, 30, and 36 were omitted from evaluation as they were either not commercially available, or purchased compounds were not readily identified by LC-MS and/or did not have acceptable purities confirmed by HPLC.
Extending from our high-throughput screening studies, we have been investigating the antibiotic potential of 22 of our initial GroEL/ES inhibitor hits (Figure 2) . We first tested the GroEL/ES inhibitors in two additional biochemical counter-screens to further support that they are acting "on-target" and are not simply artifacts or false-positives. The first counter-screen evaluates for inhibition of GroEL/ES-mediated refolding of a third stringent substrate, Rhodanese (Rho). The second counter-screen evaluates for inhibition of the native Rho enzymatic reporter reaction. Detailed protocols for these two assays are presented in the Supporting Information). [41] [42] [43] [44] For most of the compounds, we found a direct correlation between inhibition of both the GroEL/ES-mediated dMDH and dRho refolding reactions ( Table 1 and Figure 3A ). While some compounds inhibited either the native MDH or Rho reporter reactions, only compound 10 inhibited in both counter-screens, and only to a minor extent against native MDH ( Table 1 and Figure 3B ). Thus, we are confident that compounds are on-target inhibitors of dMDH and dRho refolding. We next evaluated the 22 compounds for their antibiotic effects on E. coli cells. A general bacterial proliferation assay (see the Supporting Information for a detailed protocol) was employed in liquid media using DH5E. coli cells as the initial test strain (EC50 values are summarized in Table 2 and graphically in Figure 4A ). Unfortunately, no significant inhibition of bacterial growth was observed for any of the compounds up to 100 M.
Reasoning this might be due to efflux of the molecules, we tested against an MC4100 ΔacrB E. coli strain, which has one of the central components of the AcrA/AcrB/TolC efflux pump removed.
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Compounds 8 and 18 were the most potent inhibitors of this efflux-compromised E. coli strain (EC50 = 2.3 and 21 M, respectively), with the remainder of the compounds being inactive. Table 1 . Biochemical IC50 results for E. coli GroEL/ES inhibitors. Statistical analyses (twotailed t-tests) were performed for compound log(IC50) values determined from the GroEL/ESdRho and GroEL/ES-dMDH refolding assays. Compounds for which there is a statistically significant difference between inhibition results have been marked with a "" between the two assay results being compared (p < 0.05). P-values could not be calculated for compounds marked with a "#"as one IC50 is greater than the maximum compound concentration tested. For most compounds, IC50 values are not statistically different (17/22 compounds), suggesting they are "on-target" for inhibiting the refolding of the dRho and dMDH substrates. IC50 correlations are represented graphically in Figure 3 . 
GroEL/ES-dMDH Refolding

GroEL/ES-dMDH ATPase
GroEL/ES-dRho Refolding
Native MDH Reporter Activity Native Rho Reporter Activity beyond the assay detection limits (i.e. >62.5 M for the native MDH enzymatic reporter assay, and >100 M for the native Rho enzymatic reporter assay).
That many of the most potent GroEL/ES biochemical inhibitors were ineffective against the MC4100 ΔacrB E. coli cells could be due to the presence of other efflux pumps that were still functional, as it is known that E. coli contains several classes of efflux pumps. [47] [48] [49] [50] However, another possibility is that the molecules were not able to traverse the highly impermeable lipopolysaccharide (LPS) outer membrane characteristic of Gram-negative bacteria. To probe this, we tested the compounds against a mutant SM101 lpxA2 E. coli strain, which has a temperature sensitive LpxA allele leading to compromised LPS biosynthesis at non-permissive temperatures, and consequently a greater permeability to molecules. 51, 52 We found that 10 compounds inhibited the growth of this E. coli strain, with compounds 8 and 18 still proving to be the most effective (EC50 values of 0.33 and 3.3 M, respectively). These results were further supported by the ability of many compounds to inhibit the growth of a Gram-positive bacterium, Bacillus subtilis (Table 2 and Figure 4B ), which does not contain an LPS outer membrane. That more compounds failed to inhibit either the SM101 lpxA2 E. coli or B. subtilis bacteria is putatively because of the presence of efflux pumps that were still intact for these strains, and/or the continued impermeability of compounds across the cell membranes. Information for detailed protocols). A summary of the EC50 values for compounds against these bacteria is presented in Table 3 (and graphically in Figure 4B ), with a comparison against several common antibiotics. As four of the ESKAPE pathogens are Gram-negative (K. Supporting Information). We further tested compounds against an MRSA strain (ATCC #BAA-44: HPV107 strain, SCCmec Type I, Iberian PFGE Type) and found a correlation with the methicillin susceptible S. aureus strain ( Table 3) . Table 3 . EC50 results for GroEL/ES inhibitors against the ESKAPE pathogens.
pneumoniae, A. baumannii, P. aeruginosa, and E. cloacae), it is not surprising that the
While we have identified numerous inhibitors of GroEL/ES biochemical function, several of which we now know inhibit the growth of pathogenic bacteria (in particular S. aureus and MRSA), there remained the possibility that these compounds could be toxic to host cells owing to targeting of HSP60/10. To account for this possibility, in vitro counter-screens were carried out in analogous chaperonin-mediated dMDH refolding and ATPase biochemical assays employing HSP60/10 ( Table 4) . As indicated in Figure 5A , there was a correlation observed for inhibiting both E. coli GroEL/ES and human HSP60/10; however, compounds were generally more potent at inhibiting E. coli GroEL/ES. Notably, compounds 1 and 18 displayed 12-fold and >17-fold selectivities, respectively, for inhibiting E. coli GroEL/ES over human HSP60/10.
Unfortunately, the other lead inhibitor against S. aureus and MRSA bacteria, compound 8, was only 4-fold selective. Thus, we were concerned about the cytotoxicity against human cells of 8 and other compounds that inhibited the HSP60/10 refolding cycle. Table 4 . Human HSP60/10 biochemical IC50 and liver and kidney cytotoxicity EC50 results for the GroEL/ES inhibitors. Statistical analyses (two-tailed t-tests) were performed for compound log(IC50) values determined from the GroEL/ES-dMDH and HSP60/10-dMDH refolding assays. Compounds for which there is a statistically significant difference between inhibition results have been marked with a "" between the two assay results being compared (p < 0.05). P-values could not be calculated for compounds marked with a "#"as one IC50 is greater than the maximum compound concentration tested. IC50 correlations are represented graphically in Figure 5A . To gauge for potential cytotoxicity of chaperonin inhibitors to host tissues, we next evaluated compounds in viability assays using cultured human liver (THLE-3) and kidney (HEK 293) cells. These two stable cell lines were chosen because they are derived from the two main organs responsible for drug metabolism and excretion. An Alamar Blue-based cell viability assay was employed to probe for cytotoxicity.
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We observed that inhibition of HSP60/10 biochemical activity did not directly translate into cell toxicity and that many compounds were only moderately toxic or non-toxic to both cell lines ( Table 4 and Figure 5B ). This could be due to the fact that the inner mitochondrial membrane is highly impermeable to compounds, and thus inhibitors may not be able to penetrate to the mitochondrial matrix to reach HSP60/10. In conclusion, we have investigated a subset of our previously identified inhibitors of the Figure 6 ). Furthermore, they are effective against the MRSA strain evaluated here. We are pursuing further medicinal chemistry derivatization of these GroEL/ES inhibitors to develop lead analogs with more potent antibiotic effects against S. aureus (and ideally other bacteria) that remain non-toxic to mammalian cells. Since these inhibitors were discovered in a targeted
GroEL/ES screen, we consider this the putative target, but we cannot rule out the possibility of off-target effects contributing to antibacterial potency. We are designing experiments to delineate the mechanism of action at the protein level and the mode of action at the whole cell level for these GroEL/ES inhibitors. The results presented here are encouraging, leading us to believe we can selectively target bacterial GroEL/ES chaperonin systems as an antibiotic strategy.
Supporting Information:
Supporting information associated with this article can be found in the online version, which includes tabulations of log(IC50) and log(EC50) results with standard deviations; experimental protocols for biochemical and cell-based assays; synthetic protocols and characterization data for Table S5 : Human HSP60/10 biochemical inhibition and liver and kidney cytotoxicity results for the GroEL/ES inhibitors. Statistical analyses (two-tailed t-tests) were performed for compound log(IC50) values determined from the GroEL/ES-dMDH and HSP60/10-dMDH refolding assays. Compounds for which there is a statistically significant difference between inhibition results have been marked with a "" between the two assay results being compared (p < 0.05). P-values could not be calculated for compounds marked with a "#"as one IC50 is greater than the maximum compound concentration tested. IC50 correlations are represented graphically in Figure 5A in the main text. -1573 ) and THLE-3 liver cells (ATCC CRL-11233) were used for compound toxicity assays. Antibiotics were used in following concentrations when appropriate; Kanamycin (34 μg/mL), Ampicillin (50 μg/mL), Chloramphenicol (30 μg/mL) and Streptomycin (100 μg/mL). Test compounds were purchased from commercial suppliers where available (Chembridge, ChemDiv, Ambinter, Aldrich, Asinex, and Ryan Scientific), or synthesized according to literature procedures (compounds 10, 15, 23, 24, and 25 -synthetic protocols are presented in the Supplementary Data below). Compounds 2-4, 6, 7,  12, 13, 16, 17, 21, 22, 26, 30 , and 36 were omitted from evaluation as they were either not commercially available, or purchased compounds were not readily identified by LC-MS and/or did not have acceptable purities confirmed by HPLC. For ease of comparison, compound numbering from 1-36 was maintained as presented in our previous high-throughput screening study. 
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Statistical considerations.
All IC50 (or EC50) values reported are averages of IC50 (or EC50) values determined from individual dose-response curves in replicate assays as follows: 1) Individual IC50 values from replicate assays were first log-transformed and the average log(I/EC50) values and standard deviations (SD) calculated; 2) Replicate log(I/EC50) values were evaluated for outliers using the ROUT method in GraphPad Prism 6 (Q of 10%); 3) Average IC50 (or EC50) values were then back-calculated from the average log(I/EC50) values. To compare statistical differences between log(IC50) values, two-tailed, unpaired t-tests were performed using GraphPad Prism 6 (0.05 alpha level).
Protein Expression and purification.
E. coli GroEL was expressed from a trc-promoted plasmid in DH5α E. coli cells and purified as previously reported. 1 E. coli GroES was expressed from a T7-promoted plasmid in E. coli BL21 (DE3) cells and purified as previously reported. 1 Human HSP60 was expressed from a T7-promoted plasmid in Rosetta™ 2 (DE3) E. coli cells and purified as previously reported. 2 For human HSP10 purification, pET30-HSP10 was transformed into Rosetta™ 2 (DE3) E. coli cells for over-expression. Cells were grown at 37°C in LB/Kanamycin/Chloramphenicol medium until an OD600 of 0.5 was reached, then were induced with 0.5 mM IPTG and continued to grow for 2-3 h at 37°C. The culture was centrifuged at 14,000 rpm, and the cell pellet was re-suspended in Buffer A (50 mM sodium acetate, pH 4.5, and 0.5 mM EDTA), supplemented with EDTA-free complete protease inhibitor cocktail (Roche), 100 g/ml lysozyme, 10 µL (1000 u/ml) DNAase, and lysed by sonication. Clarified cell lysate was loaded on a cation exchange column (SP Sepharose fast flow resin, GE) and eluted with linear NaCl gradient with Buffer B (sodium acetate, pH 4.5, 0.5 mM EDTA, and 1 M NaCl). Fractions containing HSP10 were concentrated, dialyzed with storage buffer (50 mM Tris-HCl, pH 7.4, and 300 mM NaCl) using 10 kDa SnakeSkin™ dialysis tubing (Thermo Scientific) and re-purified on a Superdex 200 column (HiLoad 26/600, GE) in storage buffer. The concentration of protein was determined by Coomassie Protein S10 Assay Kit (Thermo Scientific). Protein was stored at 4°C in 50 mM Tris-HCl, pH 7.4, 300 mM NaCl, and 1 mM DTT.
Evaluation of compounds in GroEL/ES and HSP60/10-mediated dMDH refolding assays.
Reagent preparation: For these assays, four primary reagent stocks were prepared: 1) GroEL/ESdMDH or HSP60/10-dMDH binary complex stock; 2) ATP initiation stock; 3) EDTA quench stock; 4) MDH enzymatic assay stock. Denatured MDH (dMDH) was prepared by 2-fold dilution of MDH (5 mg/ml, soluble pig heart MDH from Roche, product #10127248001) with denaturant buffer (7 M guanidine-HCl, 200 mM Tris, pH 7.4, and 50 mM DTT). MDH was completely denatured by incubating at room temperature for 30 min. The binary complex solutions were prepared by slowly adding the dMDH stock to a stirring stock with GroEL (or HSP60) in folding buffer (50 mM Tris-HCl, pH 7.4, 50 mM KCl, 10 mM MgCl2, and 1 mM DTT), followed by addition of GroES (or HSP10). The binary complex stocks were prepared immediately prior to use and had final protein concentrations of 83.3 nM GroEL (Mr 800 kDa) or HSP60 (Mr 400 kDa), 100 nM GroES or HSP10 (Mr 70 kDa), and 20 nM dMDH in folding buffer. For the ATP initiation stock, ATP solid was diluted into folding buffer to a final concentration of 2.5 mM. Quench solution contained 600 mM EDTA (pH 8.0). The MDH enzymatic assay stock consisted of 20 mM sodium mesoxalate and 2.4 mM NADH in reaction buffer (50 mM Tris-HCl, pH 7.4, 50 mM KCl, and 1 mM DTT).
Assay Protocol: First, 30 L aliquots of the GroEL/ES-dMDH or HSP60/10-dMDH binary complex stocks were dispensed into clear, 384-well polystyrene plates. Next, 0.5 L of the compound stocks (10 mM to 4.6 M, 3-fold dilutions in DMSO) were added by pin-transfer (V&P Scientific). The chaperonin-mediated refolding cycles were initiated by addition of 20 L of ATP stock (reagent concentrations during refolding cycle: 50 nM GroEL or HSP60, 60 nM GroES or HSP10, 12 nM dMDH, 1 mM ATP, and compounds of 100 M to 46 nM, 3-fold dilution series). After incubation for 60 minutes at 37°C, the assays were quenched by addition of 10 L of the EDTA to final concentration of 100 mM. Enzymatic activity of the refolded MDH was initiated by addition of 20 L MDH enzymatic assay stock (20 mM sodium mesoxalate and 2.4 mM NADH in reaction buffer, 50 mM Tris pH 7.4, 50 mM KCl, 1 mM DTT), and followed by measuring the NADH absorbance in each well at 340 nm using a Molecular Devices, SpectraMax Plus384 microplate reader (NADH absorbs at 340 nm, while NAD + does not). A340 measurements recorded at 0.5 minutes (start point) and at successive time points until the amount of NADH consumed reached ~90% (end point, generally between 30-60 minutes). The differences between the start and end point A340 values were used to calculate the % inhibition of the GroEL/ES or HSP60/10 machinery by the compounds. IC50 values for the test compounds were obtained by plotting the % inhibition results in GraphPad Prism 6 and analyzing by non-linear regression using the log (inhibitor) vs. response (variable slope) equation. Results presented represent the averages of IC50 values obtained from at least triplicate experiments.
Counter-screening compounds for inhibition of native MDH enzymatic activity. Reagent Preparations & Assay Protocol: Reagents were identical to those used in the GroEL/ESdMDH refolding assay described above; however, the assay protocol differed in the sequence of compound addition to the wells. Compounds were pin-transferred after the EDTA quenching step, but prior to the addition of the enzymatic reporter reagents. Thus, the refolding reactions were allowed to proceed for 60 min at 37°C in the absence of test compounds, but the enzymatic activity of the refolded MDH reporter enzyme was monitored in the presence of test compounds (inhibitor concentration range during the enzymatic reporter reaction is 83.3 µM to 38 nM -3-fold dilutions). IC50 values for the MDH reporter enzyme were determined as described above. Results presented represent the averages of IC50 values obtained from at least triplicate experiments.
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Evaluation of compounds for inhibition of chaperonin-dependent ATPase activity. Reagent preparation: For these assays, four primary reagent stocks were prepared: 1) GroEL/ESdMDH or human HSP60/10-dMDH binary complex stock; 2) ATP initiation stock; 3) EDTA quench stock; 4) malachite green reporter stock. The dMDH stock was prepared as in the above refolding assays. Binary complex solutions were immediately prepared prior to use, with final concentrations of 100 nM GroEL or HSP60, 120 nM GroES or HSP10, and 250 nM dMDH in folding buffer (50 mM Tris-HCl, pH 7.4, 50 mM KCl, 10 mM MgCl2, and 1 mM DTT). For the ATP initiation stock, ATP solid was diluted into folding buffer to a final concentration of 2 mM. Quench solution contained 300 mM EDTA (pH 8.0). The malachite green reporter stock consisted of 0.034% malachite green and 1.04% ammonium molybdate tetrahydrate in 1 M HCl with 0.02% Tween-20.
Assay protocol: First, 10 L aliquots of binary stock were dispensed into clear, flat-bottom, 384-well polystyrene plates. Next, 0.5 L of the compound stocks (10 mM to 4.6 M, 3-fold dilutions in DMSO) were added by pin-transfer. The ATP-dependent chaperonin refolding cycles were initiated by addition of 10 L ATP stock (reagent concentrations during the assay; 50 nM GroEL or HSP60, 60 nM GroES or HSP10, 125 nM dMDH, 1 mM ATP, and compounds from 250 M to 114 nM, 3-fold dilution series). The reactions were incubated at 37°C for 60 minutes, then were quenched by addition of 10 L of the EDTA solution. After quenching, 60 L of the malachite green reporter stock was added and incubated at room temperature for 15 min, then the absorption was measured at 600 nm. A second set of baseline control plates were prepared analogously, but without binary solution, to correct for possible interference from compound absorbance or turbidity. IC50 values for the test compounds were obtained by plotting the OD600 results in GraphPad Prism 6 and analyzing by non-linear regression using the log(inhibitor) vs. response (variable slope) equation. Results presented represent the averages of IC50 values obtained from at least triplicate experiments.
Evaluation of compounds in GroEL/ES in denatured Rhodanese refolding assay.
Reagent preparation: For this assay, five primary reagent stocks were prepared: 1) GroEL/ES-dRho binary complex stock; 2) ATP initiation stock; 3) thiocyanate enzymatic assay stock; 4) formaldehyde quench stock; 5) ferric nitrate reporter stock. Denatured Rhodanese (dRho) was prepared by 3-fold dilution of Rhodanese (Roche product #R1756, diluted to 10 mg/mL with H2O) with denaturant buffer (12 M Urea, 50 mM Tris-HCl, pH 7.4, and 10 mM DTT). Rhodanese was completely denatured by incubating at room temperature for 30 min. The binary complex solution was prepared by slowly adding the dRho stock to a stirring stock of concentrated GroEL in modified folding buffer (50 mM Tris-HCl, pH 7.4, 50 mM KCl, 10 mM MgCl2, 5 mM Na2S2O3 and 1 mM DTT). The solution was centrifuged at 16,000 x g for 5 minutes, and the supernatant was collected and added to a solution of GroES in modified folding buffer to give final protein concentrations of 100 nM GroEL, 120 nM GroES, and 80 nM dRho in modified folding buffer. The binary complex stock was prepared immediately prior to use. For the ATP initiation stock, ATP solid was diluted into modified folding buffer to a final concentration of 2.0 mM. The thiocyanate enzymatic assay stock was prepared to contain 70 mM KH2PO4, 80 mM KCN, and 80 mM Na2S2O3 in water. The formaldehyde quench solution contained 30% formaldehyde in water. The ferric nitrate reporter stock contained 8.5% w/v Fe(NO3)3 and 11.3% v/v HNO3 in water.
Assay Protocol: First, 10 L aliquots of the GroEL/ES-dRho complex stock was dispensed into clear, 384-well polystyrene plates. Next, 0.5 L of the compound stocks (10 mM to 4.6 M, 3-fold dilutions in DMSO) were added by pin-transfer. The chaperonin-mediated refolding cycle was initiated by addition of 10 L of ATP stock (reagent concentrations during refolding cycle: 50 nM GroEL, 60 nM GroES, 40 nM dRho, 1 mM ATP, and compounds of 250 M to 114 nM, 3-fold dilution series). After incubating for 60 minutes at 37°C for the refolding cycle, 30 L of the thiocyanate enzymatic assay S12 stock was added and incubated for 60 min at R.T. for the refolded Rhodenase enzymatic reporter reaction. The reporter reaction was quenched by adding 10 L of the formaldehyde quench stock, and then 40 L of the ferric nitrate reporter stock was added to quantify the amount of thiocyanate produced during the enzymatic reporter reaction, which is proportional to the amount of dRho refolded by GroEL/ES. After incubating at R.T. for 15 min, the absorbance by Fe(SCN)3 was measured at 460 nm using a Molecular Devices, SpectraMax Plus384 microplate reader. A second set of baseline control plates were prepared analogously, but without binary solution, to correct for possible interference from compound absorbance or turbidity. IC50 values for the test compounds were obtained by plotting the A460 results in GraphPad Prism 6 and analyzing by non-linear regression using the log(inhibitor) vs. response (variable slope) equation. Results presented represent the averages of IC50 values obtained from at least triplicate experiments.
Counter-screening compounds for inhibition of native Rhodanese enzymatic activity. Reagent Preparations & Assay Protocol: Reagents were identical to those used in the GroEL/ES-dRho refolding assay described above; however, the assay protocol differed in the sequence of compound addition to the wells. Compounds were pin-transferred after the incubation for 60 minutes at 37°C for the refolding cycle, but prior to the addition of the thiocyanate enzymatic assay stock. Thus, the refolding reactions were allowed to proceed for 60 min at 37°C in the absence of test compounds, but the enzymatic activity of the refolded Rhodanese reporter enzyme was monitored in the presence of test compounds (inhibitor concentration range during the enzymatic reporter reaction is 100 M to 46 nM -3-fold dilutions). IC50 values for the Rhodenase reporter enzyme were determined as described above. Results presented represent the averages of IC50 values obtained from at least triplicate experiments.
Evaluation of compounds for inhibition of bacterial cell proliferation.
All E.coli strains and B. subtilis 168 were grown using Luria-Bertani (LB) media broth/agar, unless specified otherwise. S. aureus and MRSA were grown using ATCC Medium 18. All other ESKAPE pathogens (E. faecium, K. pneumonia, A. baumannii, P. aeruginosa, and E. cloacae), were grown using Brain Heart Infusion media broth/agar (Becton, Dickinson and Company).
General Assay Protocol:
Stock bacterial cultures were streaked onto agar plates and grown overnight at 37°C. Fresh aliquots of broth were inoculated with single bacterial colonies and the cultures were grown overnight at 37°C with shaking (250 rpm). The following morning, the overnight cultures were sub-cultured (1:5 dilution) into fresh aliquots of media and grown at 37°C for 2 h with shaking. After 2 h, cultures were diluted into fresh media to achieve final OD600 readings of 0.0125. Aliquots of these diluted cultures (80 L) were added to clear, flat-bottom, 384-well polystyrene plates that were stamped with 1.0 L of test compounds in 20 L media (8x, 3-fold dilution series stocks ranging from 10 mM to 4.6 M in DMSO). Plates were sealed with "Breathe Easy" oxygen permeable membranes (Diversified Biotech) and left to incubate at 37°C without shaking (stagnant assay). OD600 readings were taken at the 6-8 h time points, depending on the time for each bacterial strain to reach mid-log phase growth. A second set of baseline control plates were prepared analogously, but without any bacteria added, to correct for possible compound absorbance and/or precipitation. EC50 values for the test compounds were obtained by plotting the OD600 results in GraphPad Prism 6 and analyzing by non-linear regression using the log(inhibitor) vs. response (variable slope) equation. Results presented represent the averages of EC50 values obtained from at least triplicate experiments.
Evaluation of compounds for inhibition of MC4100 ΔacrB E. coli cell growth: MC4100 ΔacrB E. coli were streaked onto an LB agar plate containing 50 g/mL kanamycin and grown overnight at 37°C. The following morning, the overnight culture was sub-cultured (1:5 dilution) into a fresh aliquot of media, without addition of antibiotic, and grown at 37°C for 2 h with shaking. After 2 h, the culture was diluted Triethylamine (0.29 mL, 2.1 mmol) was added to a stirring mixture of compound 40 (191 mg, 0.691 mmol) and triphosgene (88.8 mg, 0.299 mmol) in anhydrous DCM (7 mL), and the reaction was stirred for at R.T. (under Ar). After 2 h, ethanolamine (0.21 mL, 3.5 mmol) was added and the reaction stirred for an additional 4 h. Flash chromatographic purification over silica (hexanes:EtOAc gradient), followed by prep-HPLC purification, afforded 1-(2,3-di(furan-2-yl)quinoxalin-6-yl)-3-(2-hydroxyethyl)urea (25) as a red-orange powder (74.5 mg, 68%). 
